All In MedTech

Device Trial Radar · NCT03972527

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Radiation Therapy With or Without Concurrent Chemotherapy

Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Aug 5, 2022

Primary completion

Jun 26, 2024

Study completion Jul 18, 2024

Sponsor

Lead sponsor
MuReva Phototherapy Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jun 3, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce the severity of oral mucositis (OM) in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, tonsils and base of tongue receiving radiation therapy with or without concurrent chemotherapy.

Conditions

  • Oral Mucositis (Ulcerative)
  • Oral Mucositis (Ulcerative) Due to Radiation
  • Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
  • Head and Neck Cancer

Interventions

  • PhotobiomodulationDevice

    Provide photobiomodulation therapy to subjects prior to each radiation therapy session.

  • Routine Oral Care and AnalgesiaOther

    Standard oral care, oral hygiene and oral pain protocols

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. IThe primary effectiveness endpoint is the severity of oral mucositis at week 6 of radiation treatment according to the Oral Mucositis Index (OMI) score.Time frame: approximately 6 weeks after patient begins radiation therapy

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • The Oncology Institute

    Long Beach, California

  • Miami Cancer Institute

    Miami, Florida

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.